Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kartheeswaran Thangathurai

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Scientific Reports|July 14, 2026
OptiRanker: a simulation and optimization framework for efficient in vivo validation of drug prioritization algorithmsOhad Landau, Kartheeswaran Thangathurai, Shai Magidi, et al.
Research Square|February 24, 2023
Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapyJessica Jou, Shumei Kato, Hirotaka Miyashita, et al.
Molecular Cancer Therapeutics|August 24, 2023
Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for ImmunotherapyJessica Jou, Shumei Kato, Hirotaka Miyashita, et al.
NPJ Genomic Medicine|August 8, 2023
T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapyHirotaka Miyashita, Razelle Kurzrock, Nicholas J Bevins, et al.
American Journal of Cancer Research|June 11, 2024
The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer typesHirotaka Miyashita, Nicholas J Bevins, Kartheeswaran Thangathurai, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Scientific Reports|July 14, 2026
OptiRanker: a simulation and optimization framework for efficient in vivo validation of drug prioritization algorithmsOhad Landau, Kartheeswaran Thangathurai, Shai Magidi, et al.
Research Square|February 24, 2023
Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapyJessica Jou, Shumei Kato, Hirotaka Miyashita, et al.
Molecular Cancer Therapeutics|August 24, 2023
Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for ImmunotherapyJessica Jou, Shumei Kato, Hirotaka Miyashita, et al.
NPJ Genomic Medicine|August 8, 2023
T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapyHirotaka Miyashita, Razelle Kurzrock, Nicholas J Bevins, et al.
American Journal of Cancer Research|June 11, 2024
The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer typesHirotaka Miyashita, Nicholas J Bevins, Kartheeswaran Thangathurai, et al.
Pageof 1